According to the study, the small molecule oral JAK inhibitor baricitinib (Lilly) was found effective for patients with highly refractory rheumatoid arthritis.

“Our findings have particular relevance because of the unmet need for effective treatment of rheumatoid arthritis in patients receiving a conventional synthetic [disease-modifying anti-rheumatic drug] DMARD with inadequate disease control despite previous treatment with multiple biologic agents; the number of such patients has been consistently increasing since biologic DMARDs first became available more than 15 years ago,” Genovese and colleagues wrote.”

Click Here to read more